Benzinga | Jan 15, 2021 08:08AM EST

B of A Securities Downgrades NextCure to Underperform, Lowers Price Target to $10

B of A Securities downgrades NextCure (NASDAQ:NXTC) from Neutral to Underperform and lowers the price target from $13 to $10.